Navigation Links
U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Date:10/16/2009

WILMINGTON, Del., Oct. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

The FDA decision was based on a supplemental New Drug Application submitted by AstraZeneca which included data from the PLUTO (Pediatric Lipid-redUction Trial of rOsuvastatin) study. PLUTO was designed to evaluate the efficacy and safety of CRESTOR in children ages 10-17 with HeFH.

"AstraZeneca is committed to studying the impact of CRESTOR in various populations with a high unmet medical need, including pediatric and adolescent patients. Information about the effects of CRESTOR in pediatric patients with HeFH will now be included in the CRESTOR Prescribing Information," said Alex Gold, MD, Executive Director of Clinical Development for CRESTOR, AstraZeneca US. "While we believe it was important to investigate the use of CRESTOR in these patients, AstraZeneca does not plan to actively promote this indication."

In July, AstraZeneca announced the FDA had granted an additional six-month period of exclusivity to market CRESTOR® (rosuvastatin calcium) for its approved cholesterol and atherosclerosis indications until July 2016. The decision was based on the supplemental New Drug Application submitted by AstraZeneca.

The completion of the PLUTO study satisfied AstraZeneca's commitment to the FDA to conduct a study evaluating the impact of CRESTOR on this ped
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
6. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
10. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
11. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Type 2 Diabetes Using Emisphere,s Eligen(R) ... ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a ... study used a delivery-agent-based approach using Emisphere,s Eligen(R),technology, and was conducted ...
... meets primary endpoints in ENGAGE Trial, KENILWORTH, ... ) announced today that corifollitropin alfa, its,experimental, sustained ... Phase III ENGAGE trial, according to data presented ... of the,European Society of Human Reproduction and Embryology ...
Other Medicine Technology:Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 2Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 3
(Date:5/23/2012)... proteins of the same kind, thereby triggering skeletal and ... researchers from the RUB Heart and Diabetes Center NRW ... in an interdisciplinary research project with colleagues from the ... the Journal of Biological Chemistry . , ... forms stabilizing filaments inside of the cells. Different mutations ...
(Date:5/23/2012)... FRANCISCO Prior treatment with inhaled corticosteroids in ... pneumonia (CAP) is associated with a lower incidence ... new study from researchers in Spain. , A ... (excess fluid that accumulates between the two pleural ... that arises as a result of a pneumonia, ...
(Date:5/22/2012)... Bend Research Inc., a leading independent ... expansion of its existing hot-melt extrusion (HME) ... Leistritz twin-screw mixer/extruder. , The 18mm ... 27mm Leistritz and 19mm Baker Perkins extruder ... high-shear wet-granulation capabilities. Many projects have been ...
(Date:5/22/2012)... The uproar that began last year when the U.S. ... longer offer regular prostate-cancer tests to healthy men continued ... report. Overall, they stuck to their guns, stating that ... cancer, the PSA test, causes more harm than good ... even dangerous, treatments. , But many people simply don,t ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
Breaking Medicine News(10 mins):Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: